Reyon Pharmaceutical Co Ltd (102460) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.007x

Based on the latest financial reports, Reyon Pharmaceutical Co Ltd (102460) has a cash flow conversion efficiency ratio of -0.007x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.73 Billion ≈ $-1.17 Million USD) by net assets (₩233.12 Billion ≈ $157.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Reyon Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2008–2024)

This chart illustrates how Reyon Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 102460 current and long-term liabilities for a breakdown of total debt and financial obligations.

Reyon Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Reyon Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Compañía Minera Autlán S.A.B. de C.V MX:AUTLANB	0.022x
Texaf SA BR:TEXF	0.078x
Lu Thai Textile SHE:200726	0.016x
Lonyer Fuels SHG:603003	0.026x
ENDOMINES FINLAND OYJ EO1 F:H13	N/A
Kolibri Global Energy Inc. Common stock NASDAQ:KGEI	0.033x
Atlas Lithium Corporation Common Stock NASDAQ:ATLX	-0.129x
Manulife Holdings Bhd KLSE:1058	0.103x

Annual Cash Flow Conversion Efficiency for Reyon Pharmaceutical Co Ltd (2008–2024)

The table below shows the annual cash flow conversion efficiency of Reyon Pharmaceutical Co Ltd from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see Reyon Pharmaceutical Co Ltd market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩249.94 Billion ≈ $169.38 Million	₩-1.44 Billion ≈ $-973.03K	-0.006x	-116.52%
2023-12-31	₩248.62 Billion ≈ $168.49 Million	₩8.65 Billion ≈ $5.86 Million	0.035x	-1.31%
2022-12-31	₩247.77 Billion ≈ $167.91 Million	₩8.73 Billion ≈ $5.92 Million	0.035x	-26.06%
2021-12-31	₩245.24 Billion ≈ $166.19 Million	₩11.68 Billion ≈ $7.92 Million	0.048x	+138.35%
2020-12-31	₩230.09 Billion ≈ $155.93 Million	₩4.60 Billion ≈ $3.12 Million	0.020x	+136.47%
2019-12-31	₩222.29 Billion ≈ $150.64 Million	₩-12.18 Billion ≈ $-8.26 Million	-0.055x	-207.90%
2018-12-31	₩225.39 Billion ≈ $152.74 Million	₩11.45 Billion ≈ $7.76 Million	0.051x	-33.44%
2017-12-31	₩219.66 Billion ≈ $148.86 Million	₩16.76 Billion ≈ $11.36 Million	0.076x	+44.31%
2016-12-31	₩179.10 Billion ≈ $121.37 Million	₩9.47 Billion ≈ $6.42 Million	0.053x	-72.89%
2012-12-31	₩126.36 Billion ≈ $85.63 Million	₩24.65 Billion ≈ $16.70 Million	0.195x	+34.09%
2011-12-31	₩105.47 Billion ≈ $71.48 Million	₩15.34 Billion ≈ $10.40 Million	0.145x	+0.12%
2009-12-31	₩59.76 Billion ≈ $40.50 Million	₩8.68 Billion ≈ $5.88 Million	0.145x	+3.49%
2008-12-31	₩42.63 Billion ≈ $28.89 Million	₩5.99 Billion ≈ $4.06 Million	0.140x	--

About Reyon Pharmaceutical Co Ltd

KO:102460 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$134.11 Million

₩197.90 Billion KRW

Market Cap Rank

#18062 Global

#887 in Korea

Share Price

₩10790.00

Change (1 day)

-3.66%

52-Week Range

₩9880.00 - ₩13750.00

All Time High

₩70413.22